Cullinan Oncology Q1 net loss $58.1M; cash $503.5M; zipalertinib dose change

Cullinan Therapeutics, Inc.

2023-Q1 EPS reported -$1.42

Net loss $58.1M for Q1 2023 vs $27.1M in Q4 2022; R&D expenses $52.1M including $25M upfront for CLN-418 license.
Cash, equivalents, investments $503.5M as of March 31, 2023; runway into 2026.
Zipalertinib pivotal study now enrolling at 100mg BID only; 150mg BID cohort discontinued per safety review.
First clinical data for CLN-049 (EHA) and CLN-619 (ASCO) to be presented mid-2023.
Licensed CLN-418 from Harbour Biomed for $25M upfront plus up to $563M in milestones and royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cullinan Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Cullinan Oncology, Inc. announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-142014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.